Taurox™ Clinical Data and Experience
-
Scientific Background on Taurox™
Articles and Presentations on Taurox™
- Fatigue Reduction and Quality of Life Enhancement Following Therapy with Taurox. (Presentation at Exeter University (UK) December 2006) Floyd E. Taub, M.D., Char Tara Albert, Lesley Crowder, Suzin Mayerson Wright, Ph.D.
- Taurox SB™ -- Molecular Activity, Safety, and Efficacy, Taub, F.E.
- The Anticancer Properties of Taurox SB may be Mediated by an Immunostimulatory Mechanism, Dunn, T.M., Wormsley, S., Taub, F.E., and Pontzer, C.H. Abstract presented at the American Society for Pharmacology and Experimental Therapeutics.
- The Immunostimulatory Effects of Taurox SB™, Dunn, T. M., Taub, F. E., Pontzer, C H., Department of Cell Biology and Molecular Genetics, University of Maryland, Submitted for publication 2001
- Thesis on the Immunostimulatory Effects of Taurox SB™, Dunn, T. M., Department of Pharmacology and Experimental Therapeutics, University of Maryland at Baltimore School of Medicine, 2000
- Therapy with the Cytokine Modulator COBAT is Associated with Decreased Fatigue in Patients with Chronic Fatigue, Mayerson, S.E.; Taub, F.E.
- A Review of Sulfur Containing NanoDrugs™ - Taurox™ and Beta LT® - Molecular Activity, Safety, and Efficacy, Floyd Taub, M.D. and Suzin Mayerson, Ph.D.
Taurox™, a small organic molecule with molecular weight of 724, is a chemical combination of the nutrient taurine and a derivative of the amino acid alanine. Taurine is an important nutrient in the development and support of brain and retinal tissue while beta-alanine is a portion of Vitamin B5. The complete chemical name is carbobenzoxy-beta-alanyl taurine or COBAT. In some reports, it is called Taurox SB.
Animal Studies
In both pet animals and laboratory mice, Taurox™ was shown to be a powerful immune modulator (Knight, et al 1994; Miller, et al 1998, 1999; Taub, et al 1998, 1999, 2000). In low concentrations Taurox™ was found to modulate erythropoiesis by sustaining the proliferative potential of human BFU-E initially deprived of erythropoietin. Taurox™ also modulated immune responses as revealed by stimulation of the lysis of SRBC by murine splenocytes in cell culture and in vivo studies as a sole agent showed potent antitumor effects against melanoma and myeloma models at low doses with negligible toxicity. (Knight et al 1994)
Toxicity Studies
Taurox™ has an unusually wide margin between the effective dose and the amount of material that can be harmful.
No toxic side effects were observed following either an oral or subcutaneous single 400 ug/kg dose of Taurox™. During the 14-day post-administration period, the animals all gained the appropriate amount of weight as compared to their saline-injected controls and there was no morbidity/mortality. Following euthanasia there were no abnormal findings in the gross necropsies. Single-dose studies of Taurox™ in adult male and female CD-1 mice suggested a maximally tolerated dose (MTD) of about 150mg/kg administered as an IV bolus. Acute toxicology studies did not demonstrate an acute lethal response until doses exceeding 133 mg/kg of Taurox™ were reached. Thus, the toxic doses levels of the compounds appear high (assuming man is like a rat or mouse and not correcting for a different surface-area-to-weight ratio, a dose of 9,975 mg (10 g) would not be lethal for a 75-kg person. Typical human doses are below 1mg/person as one ten millionth of the lethal dose. In contrast, most drugs are acutely toxic at less than 100 times the normal dose.